自体肿瘤抗原负载DC-CIK细胞治疗胃癌的疗效分析  

Curative efficacy analization of autologous tumor antigen loaded DC-CIK cytotherapy for the patients with gastric cancer

作　　者：龚福生[1] 陈路川[1] 杨建伟[1] 魏晟宏[1] 谢云青[1] 林晓为[1] 应敏刚[1] 郑秋红[1] 

机构地区：[1]福建省肿瘤医院福建医科大学附属肿瘤医院福建省肿瘤生物治疗重点实验室,福建福州350014

出　　处：《中国肿瘤生物治疗杂志》2016年第6期813-818,共6页Chinese Journal of Cancer Biotherapy

基　　金：国家临床重点专科建设资助项目;福建省临床重点专科建设资助项目;福建省医学创新课题资助项目(No.2015-CXB-4)~~

摘　　要：目的:探讨自体肿瘤抗原负载树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)治疗胃癌的疗效及安全性。方法:回顾性分析2005年1月至2010年1月在福建省肿瘤医院行胃癌切除术患者270例,根据是否进行DC-CIK治疗,分为对照组(150例)和DC-CIK治疗组(120例)。应用流式细胞术分析DC-CIK细胞表型,比较两组患者的总生存期(OS),观察DC-CIK治疗的不良反应,Cox回归法分析胃癌预后影响因素。结果:成熟DC中HLA-DR^+、CD8^+、CD83^+和CD86^+的细胞比例分别为(96.16±1.51)%、(96.58±2.66)%、(96.44±2.20)%和(98.74±0.76)%。CIK中CD3^+、CD3^+CD4^+、CD3^+CD8^+和CD3^+CD16^+/CD56^+的细胞比例分别为(91.98±5.9)%、(25.19±10.5)%、(71.15±7.8)%和(18.73±7.4)%。DC-CIK治疗组中位OS为77个月,与对照组的51个月相比差异明显(χ2=4.431,P=0.035)。DC-CIK治疗、辅助化疗和TNM分期是胃癌预后的独立影响因素。DC-CIK治疗的常见不良反应为发热、寒战和乏力。结论:胃癌术后应用自体肿瘤抗原负载DC-CIK治疗可延长胃癌患者的OS,且不良反应轻,安全有效。Objective： To explore the curative effect and safety of autologous tumor antigen loaded dendritic cells com- bined with cytokine-induced killer （DC-CIK） cells in the treatment of patients with gastric cancer. Methods： Two hun- dred seventy patients who received operative resection of gastric cancer in Fujian Provincial Cancer Hospital during January, 2005 to January, 2010 were retrospectively analyzed. Acording to wether receiving DC-CIK therapy, the patients were divided into DC-CIK treatment group （ 120 cases） and control group （ 150 cases）. Flow cytometry assay was used to analyze phenotype of DC-CIK cells. Overall survival （OS） between both groups was compared. Advers reactions of the DC-CIK therapy were observed. And prognostic factors of the gastric cancer were analyzed by Cox regression model. Results： In the mature DC, the percentages of HLA-DR＋ , CD8 ＋ , CD83 ＋ and CD86＋ cells were（96.16 ± 1.51 ）% , （96.58 ± 2.66） %, （96.44 ± 2.20） % , and （98.74 ± 0.76 ） % respectively. In CIK cells, the proportions of CD3 ＋ , CD3 ＋ CD4 ＋ , CD3 ＋ CD8 ＋ and CD3 ＋ CD16 ＋/CD56 ＋ cells were （91.98 ± 5.9） %, （25.19 ±10.5 ） %, （71.15 ± 7.8 ） % and （18.73 ±7.4）% respectively. The median OS was 77 months in the DC-CIK treatment group and compared to OS median of 51 months in the control group, the difference was significant （X2 = 4.431, P 〈 0.05 ）. DC-CIK therapy, adju- vant chemotherapy and TNM stage are independent prognostic factors for gastric cancer. Common adverse reactions are fe- ver, chill and weakness in the DC-CIK therapy. Conclusion： Autologous tumor antigen-loaded DC-CIK therapy could pro-long OS of patients with gastric cancer after operation of gastric cancer, and have little adverse reactions as well as be safe- ty and effective.

关 键 词：胃癌 自体肿瘤抗原 树突状细胞 细胞因子诱导的杀伤细胞 免疫细胞治疗 

分 类 号：R735.2[医药卫生—肿瘤]